Literature DB >> 2028779

Serum osteocalcin levels in patients with GH deficiency before and during GH treatment.

A Sartorio1, A Conti, G Guzzaloni, G Faglia.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2028779     DOI： 10.1111/j.1651-2227.1991.tb11739.x

Source DB:  PubMed          Journal:  Acta Paediatr Scand        ISSN： 0001-656X


× No keyword cloud information.
  6 in total

1.  Elite volunteer athletes of different sport disciplines may have elevated baseline GH levels divorced from unaltered levels of both IGF-I and GH-dependent bone and collagen markers: a study on-the-field.

Authors:  A Sartorio; N Marazzi; F Agosti; G Faglia; C Corradini; E De Palo; S Cella; A Rigamonti; E E Muller
Journal:  J Endocrinol Invest       Date:  2004-05       Impact factor: 4.256

2.  Effects of 12 months rec-GH therapy on bone and collagen turnover and bone mineral density in GH deficient children with thalassaemia major.

Authors:  A Sartorio; G Conte; A Conti; A Masala; S Alagna; P Rovasio; G Faglia
Journal:  J Endocrinol Invest       Date:  2000-06       Impact factor: 4.256

3.  Growth hormone treatment in adults with GH deficiency: effects on new biochemical markers of bone and collagen turnover.

Authors:  A Sartorio; A Conti; M Monzani; F Morabito; G Faglia
Journal:  J Endocrinol Invest       Date:  1993-12       Impact factor: 4.256

4.  Effects of 12-month GH treatment on bone metabolism and bone mineral density in adults with adult-onset GH deficiency.

Authors:  A Sartorio; S Ortolani; E Galbiati; G Conte; V Vangeli; M Arosio; S Porretti; G Faglia
Journal:  J Endocrinol Invest       Date:  2001-04       Impact factor: 4.256

5.  New markers of bone and collagen turnover in children and adults with growth hormone deficiency.

Authors:  A Sartorio; A Conti; M Monzani
Journal:  Postgrad Med J       Date:  1993-11       Impact factor: 2.401

6.  Serum levels of bone Gla protein (osteocalcin, BGP) and carboxyterminal propeptide of type I procollagen (PICP) in acromegaly: effects of long-term octreotide treatment.

Authors:  M Terzolo; A Piovesan; G Osella; A Pia; G Reimondo; C Pozzi; C Raucci; M Torta; P Paccotti; A Angeli
Journal:  Calcif Tissue Int       Date:  1993-03       Impact factor: 4.333
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.